Progeria (Hutchinson–Gilford syndrome) – review of current literature

Dominika Dąbrowska, Dariusz Chlubek

Abstract


Hutchinson–Gilford progeria syndrome (HGPS), also known as juvenile progeria, is a genetic disorder associated with abnormalities in the structure and function of nuclear envelope proteins. The disease begins in childhood and causes rapid aging. Affected children usually appear normal at birth and in early infancy, but then grow more slowly than other children and do not gain weight at the expected rate. They develop a distinctive facial appearance, including prominent eyes, a thin nose with a curved tip, thin lips, a small chin and protruding ears. Hutchinson–Gilford progeria syndrome also causes hair loss, premature skin aging, joint abnormalities and loss of fat under the skin. This condition does not affect intellectual development or the development of motor skills such as sitting, standing and walking. It affects 1 in 4 million children worldwide and so far 150 cases have been reported, mostly boys. The average survival is 15 years. In recent years, there has been significant progress in the understanding of the molecular causes of this rare condition, which contributes to the development of new treatments for this rare condition, to the understanding of the causes of physiological aging in humans and may result in the development of new methods to slow this process.

Keywords


premature aging syndrome; progeria; Hutchinson–Gilford syndrome

Full Text:

PDF

References


Musich PR, Zou Y. Genomic instability and DNA damage responses in progeria arising from defective maturation of prelamin A. Aging (Albany NY) 2009;1(1):28-37. doi: 10.18632/aging.100012.

Arboleda G, Ramírez N, Arboleda H. The neonatal progeroid syndrome (Wiedemann–Rautenstrauch): a model for the study of human aging? Exp Gerontol 2007;42(10):939-43. doi: 10.1016/j.exger.2007.07.004.

Carrero D, Soria-Valles C, López-Otín C. Hallmarks of progeroid syndromes: lessons from mice and reprogrammed cells. Dis Model Mech 2016;9(7):719-35. doi: 10.1242/dmm.024711.

Méndez-López I, Worman HJ. Inner nuclear membrane proteins: impact on human disease. Chromosoma 2012;121(2):153-67. doi: 10.1007/s00412-012-0360-2.

Broers JLV, Ramaekers FCS, Bonne G, Yaou RB, Hutchison CJ. Nuclear lamins: laminopathies and their role in premature ageing. Physiol Rev 2006;86(3):967-1008. doi: 10.1152/physrev.00047.2005.

Mattout A, Dechat T, Adam SA, Goldman RD, Gruenbaum Y. Nuclear lamins, disease and aging. Curr Opin Cell Biol 2006;18(3):335-34. doi: 10.1016/j.ceb.2006.03.007.

Gruenbaum Y, Margalit A, Goldman RD, Shumaker DK, Wilson KL. The nuclear lamina comes of age. Nature Rev Mol Cell Biol 2005;6(1):21-31. doi: 10.1038/nrm1550.

Laminopatie PBJ. Typy lamin. http://www.laminopatie.pl/pl/laminy/laminytypy (20.08.2022).

Patni N, Xing C, Agarwal AK, Garg A. Juvenile-onset generalized lipodystrophy due to a novel heterozygous missense LMNA mutation affecting lamin C. Am J Med Genet A 2017;173(9):2517-21. doi: 10.1002/ajmg.a.38341.

DeBoy E, Puttaraju M, Jailwala P, Kasoji M, Cam M, Misteli T. Identification of novel RNA isoforms of LMNA. Nucleus 2017;8(5):573-82. doi: 10.1080/19491034.2017.1348449.

Skoczynska A, Budzisz E, Dana A, Rotsztejn H. New look at the role of progerin in skin aging. Prz Menopauzalny 2015;14(1):53-8. doi: 10.5114/pm.2015.49532.

Coppedè F. The epidemiology of premature aging and associated comorbidities. Clin Interv Aging 2013;8:1023-32. doi: 10.2147/CIA.S37213.

Progeria Research Foundation. http://www.progeriaresearch.org (20.08.2022).

Payam M. Premature aging syndromes. Encyclopedia of endocrine diseases. Elsevier; 2004. p. 58-64. doi: 10.1016/B0-12-475570-4/00053-6.

Gordon LB, Brown WT, Collins FS. Hutchinson–Gilford progeria syndrome. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, editors. GeneReviews®. Seattle (WA): University of Washington, 1993-2022.

Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, et al. Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome. Nature 2003;423(6937):293-8. doi: 10.1038/nature01629.

De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, et al. Lamin a truncation in Hutchinson–Gilford progeria. Science 2003;300(5628):2055. doi: 10.1126/science.1084125.

Vastag B. Cause of progeria’s premature aging found: expected to provide insight into normal aging process. JAMA 2003;289(19):2481-2. doi: 10.1001/jama.289.19.2481.

Alves DB, Silva JM, Menezes TO, Cavaleiro RS, Tuji FM, Lopes MA, et al. Clinical and radiographic features of Hutchinson–Gilford progeria syndrome: A case report. World J Clin Cases 2014;2(3):67-71. doi: 10.12998/wjcc.v2.i3.67.

Hennekam RCM. Hutchinson–Gilford progeria syndrome: review of the phenotype. Am J Med Genet A 2006;140(23):2603-24. doi: 10.1002/ajmg.a.313463.

Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith ACM, Perry MB, et al. Phenotype and course of Hutchinson–Gilford progeria syndrome. N Engl J Med 2008;358(6):592-604. doi: 10.1056/NEJMoa0706898.

González Morán MG. Síndrome de Progeria de Hutchinson–Gilford. Causas, investigación y tratamientos farmacológicos. Educ Quim 2014;25(4):432-9. doi: 10.1016/S0187-893X(14)70063-1.

DeBusk FL. The Hutchinson–Gilford progeria syndrome. Report of 4 cases and review of the literature. J Pediatr 1972;80(4):697-724. doi: 10.1016/s0022-3476(72)80229-4.

Greer MM, Kleinman ME, Gordon LB, Massaro J, D’Agostino RB Sr, Baltrusaitis K, et al. Pubertal Progression in Female Adolescents with Progeria. J Pediatr Adolesc Gynecol 2018;31(3):238-41. doi: 10.1016/j.jpag.2017.12.005.

Gordon LB, McCarten KM, Giobbie-Hurder A, Machan JT, Campbell SE, Berns SD, et al. Disease progression in Hutchinson–Gilford progeria syndrome: impact on growth and development. Pediatrics 2007;120(4):824-33. doi: 10.1542/peds.2007-1357.

Olive M, Harten I, Mitchell R, Beers JK, Djabali K, Cao K, et al. Cardiovascular pathology in Hutchinson–Gilford progeria: correlation with the vascular pathology of aging. Arterioscler Thromb Vasc Biol 2010;30(11):2301-9. doi: 10.1161/ATVBAHA.110.209460.

Prakash A, Gordon LB, Kleinman ME, Gurary EB, Massaro J, D’Agostino R Sr, et al. Cardiac Abnormalities in Patients With Hutchinson–Gilford Progeria Syndrome. JAMA Cardiol 2018;3(4):326-34. doi: 10.1001/jamacardio.2017.5235.

Silvera VM, Gordon LB, Orbach DB, Campbell SE, Machan JT, Ullrich NJ. Imaging characteristics of cerebrovascular arteriopathy and stroke in Hutchinson–Gilford progeria syndrome. AJNR Am J Neuroradiol 2013;34(5):1091-7. doi: 10.3174/ajnr.A3341.

Kieran MW, Gordon L, Kleinman M. New approaches to progeria. Pediatrics 2007;120(4):834-41. doi: 10.1542/peds.2007-1356.

Young SG, Fong LG, Michaelis S. Prelamin A, Zmpste24, misshapen cell nuclei, and progeria – new evidence suggesting that protein farnesylation could be important for disease pathogenesis. J Lipid Res 2005;46(12):2531-58. doi: 10.1194/jlr.R500011-JLR200.

Toth JI, Yang SH, Qiao X, Beigneux AP, Gelb MH, Moulson CL, et al. Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. Proc Natl Acad Sci USA 2005;102(36):12873-8. doi: 10.1073/pnas.0505767102.

Capell BC, Erdos MR, Madigan JP, Fiordalisi JJ, Varga R, Conneely KN, et al. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson–Gilford progeria syndrome. Proc Natl Acad Sci USA 2005;102(36):12879-84. doi: 10.1073/pnas.0506001102.

Mehta IS, Eskiw CH, Arican HD, Kill IR, Bridger JM. Farnesyltransferase inhibitor treatment restores chromosome territory positions and active chromosome dynamics in Hutchinson–Gilford progeria syndrome cells. Genome Biol 2011;12(8):R74. doi: 10.1186/gb-2011-12-8-r74.

Glynn MW, Glover TW. Incomplete processing of mutant lamin A in Hutchinson–Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. Hum Mol Genet 2005;14(20):2959-69. doi: 10.1093/hmg/ddi326.

Yang SH, Qiao X, Fong LG, Young SG. Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson–Gilford progeria syndrome mutation. Biochim Biophys Acta 2008;1781(1-2):36-9. doi: 10.1016/j.bbalip.2007.11.003.

Gordon LB, Kleinman ME, Miller DT, Neuberg DS, Giobbie-Hurder A, Gerhard-Herman M, et al. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndrome. Proc Natl Acad Sci USA 2012;109(41):16666-71. doi: 10.1073/pnas.1202529109.

Gordon LB, Massaro J, D’Agostino RB Sr, Campbell SE, Brazier J, Brown WT, et al. Impact of farnesylation inhibitors on survival in Hutchinson–Gilford progeria syndrome. Circulation 2014;130(1):27-34. doi: 10.1161/CIRCULATIONAHA.113.008285.

Dhillon S. Lonafarnib: First Approval. Drugs 2021;81(2):283-9. doi: 10.1007/s40265-020-01464-z.




DOI: https://doi.org/10.21164/pomjlifesci.888

Copyright (c) 2022 Dominika Dąbrowska, Dariusz Chlubek

License URL: https://creativecommons.org/licenses/by-nc-nd/3.0/pl/